Final - April 23, 2021
MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP) Centers for Disease Control and Prevention Atlanta, Georgia 30329 April 23, 2021 AGENDA ITEM PRESIDER/PRESENTER(s) Friday, April 23, 2021 11:00 Welcome & Introductions Dr. José Romero (ACIP Chair) Dr. Amanda Cohn (ACIP Executive Secretary, CDC) 11:30 Coronavirus Disease 2019 (COVID-19) Vaccines Introduction Dr. Beth Bell (ACIP, WG Chair) Pathogenesis and Management of Thrombosis with Thrombocytopenia Syndrome Dr. Michael Streiff, MD (Johns Hopkins University School of Medicine) (TTS) Thrombosis with thrombocytopenia syndrome (TTS) following Janssen COVID-19 Dr. Tom Shimabukuro (CDC/NCEZID) vaccine 12:30 Break 1:00 Public Comment 1:30 Break 1:45 Update on Janssen COVID-19 vaccine Dr. Mathai Mammen (Global Head of Janssen Research and Development) Dr. Joanne Waldstreicher (Johnson & Johnson Chief Medical Officer) VaST assessement Dr. Grace Lee (ACIP, VaST Co-chair) Thrombosis with thrombocytopenic syndrome (TTS) after COVID-19 vaccines: Dr. Sara Oliver (CDC/NCIRD) Applying the Evidence to Recommendation Framework Discussion VOTE Janssen COVID-19 Vaccine: Updated recommendations for use Dr. Sara Oliver (CDC/NCIRD) 5:00 Adjourn
Acronyms CDC Centers for Disease Control and Prevention CMS Centers for Medicare and Medicaid Services COVID-19 Coronavirus disease 2019 EtR Evidence to Recommendations Framework FDA Food and Drug Administration GRADE Grading of Recommendations Assessment, Development and Evaluation HRSA Health Resources and Services Administration IHS Indian Health Service NCHHSTP National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/OID] NCIRD National Center for Immunization & Respiratory Diseases [of CDC/OID] NCEZID National Center for Emerging and Zoonotic Diseases [of CDC/OID] NIAID National Institute of Allergy and Infectious Diseases OIDP Office of Infectious Disease and HIV/AIDS Policy SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 WG Work Group WHO World Health Organization VaST Vaccine Safety Technical Subgroup VE Vaccine Effectiveness
page 1 of 1